Gemvax Information

View Top Employees from Gemvax

Since 2008, GemVax & KAEL has operated as a cutting-edge research and development company developing proprietary peptide drug, GV1001, for treatment against various cancers and neurodegenerative disease including Alzheimer's disease and Progressive Supranuclear palsy. The fundamental driving purpose of our innovative pharmaceutical research is to facilitate significant improvements to human life through the introduction of advanced medical technology and innovation rooted in advanced scientific measures. At GemVax, we take pride in our proactive approach to medical research, and our progressive peptide-drug focused advancements have played a crucial role in the incessant global battle against incurable disease.

Website	http://www.gemvax.com
Revenue	$42.5 million
Employees	42 (13 on RocketReach)
Founded	1998
Address	00894 Taplip-dong, Daejeon, Daejeon, KR
Phone	+82 42-931-6287
Fax	+82 42-931-9190
Industry	Biotechnology Research, Manufacturing General, Chemical, Drug Discovery, Manufacturing, Science and Engineering, Pharmaceuticals
Keywords	Cancer Treatment, Drug Development, Alzheimers Treatment, Oncology, Therapeutic Peptides, Pharmaceutical Research, Immunotherapy, Drug Discovery, Biotechnology, Clinical Trials, Research And Development, Pharmaceutical, Biopharma, Medical Research, Life Sciences
Competitors	Roche, The Janssen Pharmaceutical Companies of Johnson & Johnson, Pfizer, Sanofi, AstraZeneca, Regeneron, Gilead Sciences, Moderna Therapeutics, Novavax, CureVac +35 more (view full list)
SIC	SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 80 Companies
NAICS	NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies